vs
Side-by-side financial comparison of Avidia Bancorp, Inc. (AVBC) and IRONWOOD PHARMACEUTICALS INC (IRWD). Click either name above to swap in a different company.
IRONWOOD PHARMACEUTICALS INC is the larger business by last-quarter revenue ($47.7M vs $26.8M, roughly 1.8× Avidia Bancorp, Inc.). Avidia Bancorp, Inc. runs the higher net margin — 22.9% vs -4.8%, a 27.7% gap on every dollar of revenue. IRONWOOD PHARMACEUTICALS INC produced more free cash flow last quarter ($74.6M vs $24.1M).
Avidia Bank is an American mutual community bank headquartered in Hudson, Massachusetts. It was founded in 2007 when it was formed by a merger between Hudson Savings Bank and Westborough Bank.
Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.
AVBC vs IRWD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | ||
|---|---|---|
| Revenue | $26.8M | $47.7M |
| Net Profit | $5.3M | $-2.3M |
| Gross Margin | — | — |
| Operating Margin | 33.3% | 14.3% |
| Net Margin | 22.9% | -4.8% |
| Revenue YoY | — | -47.3% |
| Net Profit YoY | — | -200.9% |
| EPS (diluted) | — | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $26.8M | $47.7M | ||
| Q3 25 | $28.0M | $122.1M | ||
| Q2 25 | $25.9M | $85.2M | ||
| Q1 25 | $22.9M | $41.1M | ||
| Q4 24 | — | $90.5M | ||
| Q3 24 | — | $91.6M | ||
| Q2 24 | — | $94.4M | ||
| Q1 24 | — | $74.9M |
| Q4 25 | $5.3M | $-2.3M | ||
| Q3 25 | $-907.0K | $40.1M | ||
| Q2 25 | $3.9M | $23.6M | ||
| Q1 25 | $-11.6M | $-37.4M | ||
| Q4 24 | — | $2.3M | ||
| Q3 24 | — | $3.6M | ||
| Q2 24 | — | $-860.0K | ||
| Q1 24 | — | $-4.2M |
| Q4 25 | 33.3% | 14.3% | ||
| Q3 25 | -7.0% | 61.8% | ||
| Q2 25 | 19.4% | 53.2% | ||
| Q1 25 | -72.0% | -70.7% | ||
| Q4 24 | — | 34.8% | ||
| Q3 24 | — | 28.0% | ||
| Q2 24 | — | 26.5% | ||
| Q1 24 | — | 14.7% |
| Q4 25 | 22.9% | -4.8% | ||
| Q3 25 | -3.2% | 32.8% | ||
| Q2 25 | 15.0% | 27.7% | ||
| Q1 25 | -50.5% | -90.9% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | — | 4.0% | ||
| Q2 24 | — | -0.9% | ||
| Q1 24 | — | -5.6% |
| Q4 25 | — | $0.01 | ||
| Q3 25 | $-0.05 | $0.23 | ||
| Q2 25 | — | $0.14 | ||
| Q1 25 | — | $-0.23 | ||
| Q4 24 | — | $0.03 | ||
| Q3 24 | — | $0.02 | ||
| Q2 24 | — | $-0.01 | ||
| Q1 24 | — | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | ||
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $275.0M | $215.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $379.0M | $-261.8M |
| Total Assets | $2.8B | $396.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $275.0M | $215.5M | ||
| Q3 25 | $208.3M | $140.4M | ||
| Q2 25 | $592.5M | $92.9M | ||
| Q1 25 | — | $108.5M | ||
| Q4 24 | — | $88.6M | ||
| Q3 24 | — | $88.2M | ||
| Q2 24 | — | $105.5M | ||
| Q1 24 | — | $121.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | $199.5M | ||
| Q2 25 | — | $199.3M | ||
| Q1 25 | — | $199.2M | ||
| Q4 24 | — | $199.0M | ||
| Q3 24 | — | $198.8M | ||
| Q2 24 | — | $198.6M | ||
| Q1 24 | — | $398.3M |
| Q4 25 | $379.0M | $-261.8M | ||
| Q3 25 | $372.0M | $-264.2M | ||
| Q2 25 | $191.4M | $-308.2M | ||
| Q1 25 | $186.1M | $-334.1M | ||
| Q4 24 | — | $-301.3M | ||
| Q3 24 | — | $-311.3M | ||
| Q2 24 | — | $-321.7M | ||
| Q1 24 | — | $-330.5M |
| Q4 25 | $2.8B | $396.9M | ||
| Q3 25 | $2.8B | $396.1M | ||
| Q2 25 | $3.0B | $342.9M | ||
| Q1 25 | $2.7B | $327.2M | ||
| Q4 24 | — | $350.9M | ||
| Q3 24 | — | $389.5M | ||
| Q2 24 | — | $395.6M | ||
| Q1 24 | — | $438.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | ||
|---|---|---|
| Operating Cash FlowLast quarter | $28.4M | $74.6M |
| Free Cash FlowOCF − Capex | $24.1M | $74.6M |
| FCF MarginFCF / Revenue | 89.9% | 156.3% |
| Capex IntensityCapex / Revenue | 16.0% | 0.0% |
| Cash ConversionOCF / Net Profit | 5.32× | — |
| TTM Free Cash FlowTrailing 4 quarters | $40.2M | $127.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.4M | $74.6M | ||
| Q3 25 | $24.1M | $47.6M | ||
| Q2 25 | $-2.3M | $-15.1M | ||
| Q1 25 | $-2.2M | $20.0M | ||
| Q4 24 | — | $15.2M | ||
| Q3 24 | — | $9.9M | ||
| Q2 24 | — | $33.5M | ||
| Q1 24 | — | $45.0M |
| Q4 25 | $24.1M | $74.6M | ||
| Q3 25 | $23.3M | $47.6M | ||
| Q2 25 | $-3.3M | $-15.1M | ||
| Q1 25 | $-3.9M | $19.9M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $9.9M | ||
| Q2 24 | — | $33.4M | ||
| Q1 24 | — | $44.9M |
| Q4 25 | 89.9% | 156.3% | ||
| Q3 25 | 83.2% | 39.0% | ||
| Q2 25 | -12.8% | -17.7% | ||
| Q1 25 | -16.9% | 48.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 10.8% | ||
| Q2 24 | — | 35.4% | ||
| Q1 24 | — | 60.0% |
| Q4 25 | 16.0% | 0.0% | ||
| Q3 25 | 3.1% | 0.0% | ||
| Q2 25 | 3.7% | 0.0% | ||
| Q1 25 | 7.2% | 0.1% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | 5.32× | — | ||
| Q3 25 | — | 1.19× | ||
| Q2 25 | -0.60× | -0.64× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 6.74× | ||
| Q3 24 | — | 2.71× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.